Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma

  1. Kröger, N.
  2. Perez-Simon, J.A.
  3. Myint, H.
  4. Klingemann, H.
  5. Shimoni, A.
  6. Nagler, A.
  7. Martino, R.
  8. Alegre, A.
  9. Tomas, J.F.
  10. Schwerdtfeger, R.
  11. Kiehl, M.
  12. Fauser, A.
  13. Sayer, H.G.
  14. Leon, A.
  15. Beyer, J.
  16. Zabelina, T.
  17. Ayuk, F.
  18. San Miguel, J.F.
  19. Brand, R.
  20. Zander, A.R.
Journal:
Biology of Blood and Marrow Transplantation

ISSN: 1083-8791

Year of publication: 2004

Volume: 10

Issue: 10

Pages: 698-708

Type: Article

DOI: 10.1016/J.BBMT.2004.06.002 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

Data source: Scopus